

Supplementary Table 1. Inhibition of trypanothione synthetase (TryS) by *N*⁵-substituted, 3-chlorokenpaullones.

<i>N</i> ⁶ -linker chain	Compound	<i>N</i> ⁵ -substitution	% TryS inhibition at 30 μM ^a or IC ₅₀ value (μM) ^{b,c}	
			<i>Tc</i> TryS	<i>Tb</i> TryS
none	1	H	NA	NA
	2	CH ₂ CH ₂ OH	NA	NA
	3	R ₁ = H	~ 30	NA
CH ₂ CO-OR ₁	4	R ₁ = CH ₃	37.4 ± 2.6	17.1 ± 4.0
	5	R ₁ = CH ₂ CH ₃	19.1 ± 5.5	29.8 ± 5.5
	6	R ₁ = <i>tert</i> -butyl	10.3 ± 5.8	NA
	7	R ₁ = H, R ₂ = H	5.2 ± 1.2	14.5 ± 5.5
CH ₂ CO-NR ₁ ,R ₂	8	R ₁ = H, R ₂ = NH ₂	10.1 ± 3.1	8.3 ± 5.8
	9	R ₁ = H, R ₂ = CH ₃	22.8 ± 2.3	44.4 ± 3.6
	10	R ₁ = CH ₃ , R ₂ = CH ₃	14.9 ± 6.5	24.6 ± 3.8
	11	R ₁ = H, R ₂ = CH ₂ CH ₃	41.4 ± 8.3	NA
	12	R ₁ = CH ₂ CH ₃ , R ₂ = CH ₂ CH ₃	7.8 ± 2.6	~ 30
	13	R ₁ = H, R ₂ = (CH ₂) ₂ OH	NA	NA
	14	R ₁ = H, R ₂ = C-(CH ₂ OH) ₃	NA	12.6 ± 7.0
	15	R ₁ = H, R ₂ = <i>tert</i> -butyl	5.8 ± 3.3	10.9 ± 6.8
	16	R ₁ = H, R ₂ = 1,3,4-thiadiazol-2-yl	~ 30	18.8 ± 3.3
	17	R ₁ = H, R ₂ = 4,5-dihydro-1,3-thiazol-2-yl	16 ± 2.2	41.3 ± 5.6
	18	R ₁ = H, R ₂ = 1,3-oxazol-2-yl	6.9 ± 3.9	12.2 ± 6.5
	19	R ₁ = H, R ₂ = phenyl	29.6 ± 2.5	~ 30
CH ₂ CO-R ₁	20	R ₁ = piperazin-1-yl, hydrochloride	17.1 ± 4.9	~ 30
	21	R ₁ = 4-methylpiperazin-1-yl	NA	31.6 ± 6.0
	22	R ₁ = 4-BOC-piperazin-1-yl	NA	18.7 ± 1.9
	23	R ₁ = 4-(pyrimidin-2-yl)piperazin-1-yl	40.6 ± 3.7	27.3 ± 3.9
	24	R ₁ = piperidin-1-yl	7.1 ± 4.5	19.9 ± 2.5
	25	R ₁ = pyrrolidin-1-yl	NA	9.8 ± 2.8
	26	R ₁ = morpholin-4-yl	NA	NA
CH ₂ CO-NH-CH ₂ -CH ₂ -NR ₁ ,R ₂	Mol2008 ^d	R ₁ = H, R ₂ = CH ₃	40.5 ± 5.9	59.0 ± 6.0
	27	R ₁ = H, R ₂ = H, hydrochloride	26.3 ± 3.6	27.3 ± 5.9
	28	R ₁ = CH ₂ CH ₃ , R ₂ = CH ₂ CH ₃	17.1 ± 1.1	16.0 ± 5.6
	29	R ₁ = H, R ₂ = BOC	38.5 ± 4.5	28.3 ± 3.2
CH ₂ CO-NH-CH ₂ -CH ₂ -R ₁	30	R ₁ = morpholin-4-yl	11.3 ± 5.1	6.1 ± 4.9
	31	R ₁ = piperidin-1-yl	21.4 ± 0.0	20.5 ± 3.2
	32	R ₁ = piperazin-1-yl, dihydrochloride	7.9 ± 8.4	NA
	33	R ₁ = 4-methylpiperazin-1-yl	16.8 ± 5.7	8.1 ± 6.2
	34	R ₁ = 4-BOC-piperazin-1-yl	20 ± 3	24.8 ± 3.6
CH ₂ CO-NH(CH ₂) ₄ -NH-R ₁	35	R ₁ = H, hydrochloride	6.7 ± 8.8	10.8 ± 2.2
	36	R ₁ = BOC	25 ± 3	27.9 ± 4.6

^a Enzyme inhibition is expressed as % TryS inhibition ± 2σⁿ⁻¹. ^b IC₅₀ values with their corresponding standard deviation (± 2σⁿ⁻¹) are highlighted in bold italics. ^c For compounds inhibiting TryS by 50 ± 5% at 30 μM, an IC₅₀ of ~ **30** μM is assumed. ^d Data published in ²⁰. NA, not active (enzyme activity at 30 μM is > 95%). BOC, refers to a *tert*-butyloxycarbonyl group.




Figure S1. Mode of *L*/TryS inhibition by compound 20. Lineweaver-Burk reciprocal plots for the *L*/TryS activity measured at different inhibitor (black square: 0 μM , red circle: 0.31 μM , blue triangle: 0.775 μM , violet star: 1.55 μM , green inverted triangle: 2.3 μM and magenta inclined triangle: 3.1 μM) and varying substrate concentrations while maintaining fixed the concentration of the co-substrates. The maximum concentration of SP and ATP used in these studies that do not interfere with the colorimetric assay were 13 mM (~ 9.1 -fold the K_M value) and 200 μM (~ 4.6 -fold the K_M value), respectively. For GSH, the maximum concentration tested was 100 μM because at higher values there is a marked enzyme inhibition and loss of linearity. The enzyme velocities were measured using the end-point assay based on BIOMOL GREEN™ reagent (Enzo Life Sciences) and the reciprocal plots are shown for the varying substrate: **A**) GSH, **B**) ATP, **C**) SP.